STOCKHOLM, Sweden, Nov. 01, 2005 (PRIMEZONE) -- Active Biotech (Stockholm: ACTI) management present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Tuesday, November 8 at 3:30 p.m. (ET) / 21.30 (CET) at The New York Palace Hotel in New York City. During the presentation, management will provide an update on the Active Biotech development program, as well as offer insight into its financial results.
The presentation will include an update on the following drugs: laquinimod, the company's oral MS drug for which it is in partnership with Teva Pharmaceutical Industries Ltd.; ANYARA, Active Biotech's novel concept for the treatment of lung cancer; and other key projects in clinical development, such as TASQ, for prostate cancer; 57-57, for Lupus (SLE); and RhuDex(R) (licensed to Avidex Ltd.) for rheumatoid arthritis.
The Active Biotech audio and slide presentation will be web cast live on November 8 at 3:30 p.m. (ET) / 21.30 (CET). A replay will beavailable approximately one hour following the presentation and archived on the company's web site. To access the live and replay presentations, visit the Active Biotech web sitewww.activebiotech.com.
About Active Biotech
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex(R) for RA.